ABIOMED, Inc. - Common Stock (NQ:ABMD)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 21, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about ABIOMED, Inc. - Common Stock

< Previous 1 2 Next >

FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial

December 21, 2022

From Abiomed, Inc.

Via Business Wire

Can Pfizer, Johnson & Johnson Continue Outperforming the Index?

December 09, 2022

Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months.

Via MarketBeat

First Patients in the World Treated with Impella RP Flex with SmartAssist

December 05, 2022

From Abiomed, Inc.

Via Business Wire

ABIOMED INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abiomed, Inc. - ABMD

November 16, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

S&P 500 Component DexCom Set For Further Price, Earnings Growth

November 13, 2022

Glucose monitor maker DexCom surged 19% after its Q3 report, and shares are holding those gains. Wall Street sees more growth ahead in 2023.

Via MarketBeat

Topics Stocks

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD), Atlas Corp. (NYSE - ATCO)

November 08, 2022

From Brodsky & Smith LLC

Via GlobeNewswire

ABIOMED INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abiomed, Inc. - ABMD

November 01, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

Johnson & Johnson (NYSE: JNJ) Set to Acquire Abiomed (NASDAQ: ABMD) for $16.6 Billion or $380 per Share Plus CVR

November 01, 2022

Abiomed, Inc. (NASDAQ: ABMD) is engaged as a medical technology company, which is focused on providing support and resources to

Via Spotlight Growth

ABMD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ABIOMED, Inc. Is Fair to Shareholders

November 01, 2022

From Halper Sadeh LLC

Via Business Wire

Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year

November 01, 2022

From Abiomed, Inc.

Via Business Wire

Johnson & Johnson to Acquire Abiomed

November 01, 2022

From Johnson & Johnson

Via Business Wire

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

October 31, 2022

From Abiomed, Inc.

Via Business Wire

Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare

October 26, 2022

From Abiomed, Inc.

Via Business Wire

MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson

October 24, 2022

From Abiomed, Inc.

Via Business Wire

Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

October 20, 2022

From Abiomed, Inc.

Via Business Wire

U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath

October 17, 2022

From Abiomed, Inc.

Via Business Wire

Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support

October 13, 2022

From Abiomed, Inc.

Via Business Wire

Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification

October 13, 2022

From Abiomed, Inc.

Via Business Wire

Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%

September 20, 2022

From Abiomed, Inc.

Via Business Wire

Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%

September 19, 2022

From Abiomed, Inc.

Via Business Wire

Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients

September 17, 2022

From Abiomed, Inc.

Via Business Wire

FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)

September 16, 2022

From Abiomed, Inc.

Via Business Wire

TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery

September 13, 2022

From Abiomed, Inc.

Via Business Wire

Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

August 16, 2022

From Abiomed

Via Business Wire

ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*

August 04, 2022

From Abiomed, Inc.

Via Business Wire

Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification

July 14, 2022

From Abiomed, Inc.

Via Business Wire

Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps

June 14, 2022

From Abiomed, Inc.

Via Business Wire

Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference

May 31, 2022

From Abiomed, Inc.

Via Business Wire

SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes

May 18, 2022

From Abiomed

Via Business Wire

Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year

April 28, 2022

From Abiomed, Inc.

Via Business Wire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.